NCT05721170 (BETA-TAVI) is a Phase 4 clinical trial of Beta blocker in Aortic Valve Stenosis, sponsored by National and Kapodistrian University of Athens.

Who is sponsoring NCT05721170?

NCT05721170 is sponsored by National and Kapodistrian University of Athens.

What drugs are being tested in NCT05721170?

Interventions in NCT05721170: Beta blocker.

What condition does NCT05721170 study?

NCT05721170 studies Aortic Valve Stenosis.

Is NCT05721170 still recruiting?

NCT05721170 is currently recruiting now. Last updated 9 December 2024.

Last reviewed 2024-12-09 · How we verify

NCT05721170: BETA-TAVI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Beta Blockers on TAVI (BETA-TAVI)

Recruiting now Phase 4 Last updated 9 December 2024

What this trial tests

Phase 4 trial testing Beta blocker in Aortic Valve Stenosis in 347 participants. Currently enrolling.

Timeline

1 June 2024

Primary endpoint
30 January 2028

31 January 2028

Quick facts

Lead sponsor	National and Kapodistrian University of Athens
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	347
Start date	1 June 2024
Primary completion	30 January 2028
Estimated completion	31 January 2028
Sites	2 locations across Greece, Cyprus

Drugs / interventions tested

Beta blocker — full drug profile →

Conditions studied

Aortic Valve Stenosis — all drugs for Aortic Valve Stenosis →

Sponsor

National and Kapodistrian University of Athens

Who can join

18 and older, any sex, with Aortic Valve Stenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, multicentre, investigator-initiated, randomized clinical trial clinical trial investigating the impact of beta-blockers administration among patients undergoing TAVI for severe aortic valve stenosis. Adults already receiving beta-blockers be assigned randomly in 1:1 ratio to either continue or withdraw the beta-blockers medication at least 72 hours before and at least 7 days after TAVI. The primary endpoint is permanent pacemaker implantation rates in 7 days after the procedure. Secondary endpoints include death, cardiogenic shock and arrhythmias/conduction abmormalities with time frame 12 months.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Transcatheter Aortic Valve Implantation and Conduction Disturbances: Focus on Clinical Implications.
Halapas A, Koliastasis L, Doundoulakis I, Antoniou CK, et al · · 2023 · cited 9× · PMID 37998527 · DOI 10.3390/jcdd10110469
Management of conduction disturbances after TAVI: the last step towards early discharge.
Muntané-Carol G, Romaguera R, Gómez-Hospital JA, Nuche J, et al · · 2025 · PMID 40607130 · DOI 10.26599/1671-5411.2025.05.004

Verify or expand the search:

Other trials of Beta blocker

Trials testing the same drug.

NCT05019027 — N-of-1 for Beta-Blockers in Cardiac Amyloidosis · Phase 4 · enrolling by invitation
NCT05786417 — LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions · Phase 4 · recruiting
NCT06371222 — Role of Ivabradine on Heart Rate and Quality of Life in Patients With Mitral Stenosis in Sinus Rhythm · Phase 4 · completed
NCT04575675 — Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy · Phase 4 · completed
NCT04286399 — Asian Diabetes Outcomes Prevention Trial · Phase 4 · recruiting

Other recruiting trials for Aortic Valve Stenosis

Currently open trials in the same condition.

NCT07455292 — Phenotyping Left Ventricle Failure With Hemodynamic Biomarkers From 4D Flow Magnetic Resonance Imaging · NA · recruiting
NCT07008911 — CardioHeartConnect: Commercially Available Fitness for Cardiac Rehabilitation · NA · recruiting
NCT07145463 — Prospective, Multicenter, Randomized Controlled Clinical Study Evaluating the VitaFlow Liberty® Flex Transcatheter Aorti · NA · recruiting
NCT07520656 — Impact of Transcatheter Aortic Valve Implantation and Mitral Valve Repair on Sleep-Disordered Breathing · recruiting
NCT07267117 — Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease · recruiting

Other National and Kapodistrian University of Athens trials

Trials by the same sponsor.

NCT07295964 — Accuracy of Intraoral Scan Post-processing Methods: A Clinical Trial · NA · not yet recruiting
NCT07351981 — TcPRF for Knee Osteoarthritis · NA · enrolling by invitation
NCT07477496 — Recurrence and Anal Fistula Patient Reported Outcomes Trial · recruiting
NCT07295899 — Assessing the Influence of Implant Scanning Techniques on the Accuracy of Maxillary Complete-Arch Digital Scans for Impl · not yet recruiting
NCT06903130 — Clinical Study to Evaluate the Effects of the Complement C5 Inhibitor Ravulizumab on Serum Neurofilament Light Chain (sN · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05721170 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National and Kapodistrian University of Athens
Last refreshed: 9 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05721170.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing